Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emcure PharmaceuticalsNSE:EMCURE -0.04%41 EV-to-EBIT is 24.70 as of Sep. 08, 2026, which is 9% above its 10-year median of 22.59. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Emcure Pharmaceuticals ranks worse than 66.08% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Emcure Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was ₹348,252 Mil.
Emcure Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹15,384 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emcure Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Emcure Pharmaceuticals's EV-to-EBIT falls into.
Emcure Pharmaceuticals's current Enterprise Value is ₹380,026 Mil.
Emcure Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹15,384 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emcure Pharmaceuticals (NSE:EMCURE) has a EV-to-EBIT of 24.70 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Emcure Pharmaceuticals and its competitors. This is near median its historical median of 22.59. Over the past decade, Emcure Pharmaceuticals' EV-to-EBIT has ranged from 16.07 to 28.94. According to the industry distribution chart, Emcure Pharmaceuticals ranks #450 out of 681 companies in the Drug Manufacturers industry, placing it in the top 66.1%.
Is Emcure Pharmaceuticals' EV-to-EBIT too high?
Emcure Pharmaceuticals' current EV-to-EBIT of 24.70 is near median its 10-year median of 22.59. Over the past 10 years, this metric has ranged from a low of 16.07 to a high of 28.94. The Drug Manufacturers industry median EV-to-EBIT is 16.01. Emcure Pharmaceuticals' value of 24.70 is 54.3% above this industry median. Based on the distribution chart, Emcure Pharmaceuticals ranks #450 out of 681 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #450 out of 681 companies for EV-to-EBIT. This places Emcure Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 16.01. Emcure Pharmaceuticals' value of 24.70 is 54.3% above this benchmark. Historically, Emcure Pharmaceuticals' own EV-to-EBIT has ranged from 16.07 to 28.94 over the past decade. While the company's 10-year median is 22.59 vs. the industry median of 16.01, Emcure Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.01, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emcure Pharmaceuticals's current EV-to-EBIT of 24.70 is 54.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Emcure Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emcure Pharmaceuticals's current EV-to-EBIT is 24.70, which is near median its own 10-year median of 22.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current EV-to-EBIT of 24.70. The current EV-to-EBIT is 24.70, which is near median its 10-year median of 22.59 and 54.3% above the Drug Manufacturers industry median of 16.01. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current EV-to-EBIT is 24.70 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score
Get the complete analysis for NSE:EMCURE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EMCURE has been successfully added to your 
